Skip to main content
. Author manuscript; available in PMC: 2017 Jul 11.
Published in final edited form as: Exp Neurol. 2011 Nov 4;233(1):357–363. doi: 10.1016/j.expneurol.2011.10.029

Fig. 5.

Fig. 5

Microclot burden (#/mm3) for each experimental group. Compared to controls (23 microclots/mm3), microclot burden was lower in the scFv/uPA-T and scFv/uPA-T+clazosentan groups (each approximately 5 microclots/mm3 and higher in the clazosentan group (33 microclots/mm3). Significant differences were observed between all groups except scFv/uPA-T and scFv/uPA-T+clazosentan. On the x-axis, uPA refers to scFv/uPA-T.